Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

It is recommended to evaluate whether there are vertebral fractures soon after initiating GC therapyD18.6During GC therapy, it is recommended to measure bone mineral density by dual-energy X-ray absorptiometry regularlyD18.45What is the guidance on lifestyle and nutrition for patients with GIOP?It is recommended to prioritize the treatment of the primary disease, which is the reason for the administration of GCs, and to guide lifestyle, including nutrition, according to the disease characteristics of the primary diseaseD19.0It is recommended to guide lifestyle and nutrition according to the Japanese guidelines for preventing and treating osteoporosisD19.06What are the criteria for initiating drug therapy for GIOP?It is recommended to use the cut-off scores described in the “Guidelines on the management and treatment of GIOP of the JSBMR: 2014 update" as the criteria for initiating drug therapy for GIOPC19.07Are active vitamin D preparations useful for treating GIOP?Active vitamin D preparations, such as eldecalcitol, are recommended because they effectively increase the bone mineral density of the lumbar spine and prevent non-vertebral fractures in patients scheduled to receive GC therapy and patients receiving GC therapyB18.08Are bisphosphonates useful for the treatment of GIOP?Bisphosphonates are recommended for patients scheduled to receive GC therapy or patients receiving GC therapy because there is evidence for the effects of bisphosphonates in increasing the bone mineral density of the lumbar spine and femur and preventing vertebral and non-vertebral fracturesA19.09Are selective estrogen receptor modulators useful for the treatment of GIOP?Although there is no evidence that selective estrogen receptor modulators (SERMs) are effective for preventing vertebral or non-vertebral fractures in postmenopausal women at risk of GIOP, they are effective for increasing the bone mineral density of the lumbar spine and femur.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Study design awaiting verification · Journal of Bone and Mineral Metabolism · 2024

Original publication title

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Yoshiya Tanaka; Satoshi Soen; Shintaro Hirata; Yosuke Okada; Saeko Fujiwara; Ikuko Tanaka; Yuriko Kitajima; Takuo Kubota; Kosuke Ebina; Yuichi Takashi; Reiko Inoue; Mika Yamauchi; Naoaki Okubo; Masanobu Ueno; Yasuhisa Ohata; Nobuaki Ito; Keiichi Ozono; Hisanori Nakayama; Masakazu Terauchi; Sakae Tanaka; Seiji Fukumoto

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The 2023 guidelines for the management and treatment of GIOP was developed through systematic reviews and consensus conferences using the Delphi method.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30 to 50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months.

Source: Introduction

Abstract: What methods does the paper describe?

The Committee on the revision of the guidelines for the management and treatment of GIOP of the JSBMR prepared 17 clinical questions (CQs) according to the GRADE approach and revised the guidelines for the management and treatment of GIOP through systematic reviews and consensus conferences using the Delphi method.

Source: Materials and methods

Abstract: Results

Bisphosphonates (oral and injectable formulations), anti-RANKL antibody teriparatide, eldecalcitol, or selective estrogen receptor modulators are recommended for patients who has received or scheduled for GC therapy with risk factor scores of ≥3. It is recommended that osteoporosis medication is started concomitantly with the GC therapy for the prevention of fragility fractures in elderly patients.

Source: Results

Abstract: Conclusion

The 2023 guidelines for the management and treatment of GIOP was developed through systematic reviews and consensus conferences using the Delphi method.

Source: Conclusion
Authors’ abstract

Introduction

Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30 to 50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months.

Materials and methods

The Committee on the revision of the guidelines for the management and treatment of GIOP of the JSBMR prepared 17 clinical questions (CQs) according to the GRADE approach and revised the guidelines for the management and treatment of GIOP through systematic reviews and consensus conferences using the Delphi method.

Results

Bisphosphonates (oral and injectable formulations), anti-RANKL antibody teriparatide, eldecalcitol, or selective estrogen receptor modulators are recommended for patients who has received or scheduled for GC therapy with risk factor scores of ≥3. It is recommended that osteoporosis medication is started concomitantly with the GC therapy for the prevention of fragility fractures in elderly patients.

Conclusion

The 2023 guidelines for the management and treatment of GIOP was developed through systematic reviews and consensus conferences using the Delphi method.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00774-024-01502-w.

Publication and source details

Original title: The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Yoshiya Tanaka; Satoshi Soen; Shintaro Hirata; Yosuke Okada; Saeko Fujiwara; Ikuko Tanaka; Yuriko Kitajima; Takuo Kubota; Kosuke Ebina; Yuichi Takashi; Reiko Inoue; Mika Yamauchi; Naoaki Okubo; Masanobu Ueno; Yasuhisa Ohata; Nobuaki Ito; Keiichi Ozono; Hisanori Nakayama; Masakazu Terauchi; Sakae Tanaka; Seiji Fukumoto

Journal of Bone and Mineral Metabolism · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Japanese Society for Bone and Mineral Research

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:30:02.840615+00:00

DOI: 10.1007/s00774-024-01502-w · PMC10982086